MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Bosutinib In Subjects With Renal Impairment

Phase 1
Completed
Conditions
Renal Disease, End-Stage
Renal Insufficiency, Chronic
Renal Insufficiency, Acute
Interventions
First Posted Date
2010-11-03
Last Posted Date
2012-07-03
Lead Sponsor
Pfizer
Target Recruit Count
34
Registration Number
NCT01233882
Locations
🇺🇸

Pfizer Investigational Site, Saint Paul, Minnesota, United States

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

First Posted Date
2010-11-02
Last Posted Date
2019-01-08
Lead Sponsor
Pfizer
Target Recruit Count
338
Registration Number
NCT01232556
Locations
🇺🇸

Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services, Los Angeles, California, United States

🇺🇸

University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States

🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 165 locations

Safety And Tolerability Of Multiple Dose Lersivirine For 21 Days In Healthy Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2010-10-29
Last Posted Date
2011-05-17
Lead Sponsor
Pfizer
Target Recruit Count
75
Registration Number
NCT01230385
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)

Completed
Conditions
Arthritis
Rheumatoid
Interventions
First Posted Date
2010-10-28
Last Posted Date
2017-02-23
Lead Sponsor
Pfizer
Target Recruit Count
3
Registration Number
NCT01230177
Locations
🇯🇵

Taihaku Sakura Hospital, Sendai, Miyagi, Japan

Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)

Phase 3
Completed
Conditions
Dupuytren's Contracture
Interventions
Drug: Xiapex
First Posted Date
2010-10-27
Last Posted Date
2014-03-17
Lead Sponsor
Pfizer
Target Recruit Count
254
Registration Number
NCT01229436
Locations
🇬🇧

Pfizer Investigational Site, Southampton, United Kingdom

Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients

Completed
Conditions
HIV Infection
Interventions
First Posted Date
2010-10-25
Last Posted Date
2013-04-26
Lead Sponsor
Pfizer
Target Recruit Count
476
Registration Number
NCT01227395

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Other: Placebo- Phosphate buffered saline (PBS)
Biological: ACC-001 10 μg/ QS-21 50 μg
Biological: ACC-001 3 μg/ QS-21 50 μg
First Posted Date
2010-10-25
Last Posted Date
2016-02-25
Lead Sponsor
Pfizer
Target Recruit Count
63
Registration Number
NCT01227564
Locations
🇺🇸

Banner Lakes Imaging Center, Sun City, Arizona, United States

🇺🇸

Universal Medical Center, Tucson, Arizona, United States

🇺🇸

Internal Medicine Associates of Lee County, MD, PA, Fort Myers, Florida, United States

and more 37 locations

Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes

Phase 2
Terminated
Conditions
Hepatitis C, Chronic
Interventions
Drug: Placebo
First Posted Date
2010-10-22
Last Posted Date
2023-07-27
Lead Sponsor
Pfizer
Target Recruit Count
24
Registration Number
NCT01226797
Locations
🇰🇷

Severance Hospital, Yonsei University College of Medicine, Division of Gastroenterology, Seoul, Korea, Republic of

🇮🇳

Institute of Liver & Biliary Sciences, New Delhi, India

🇸🇬

Singapore General Hospital, Singapore, Singapore

and more 7 locations

A Study In Healthy Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of Three Formulations Of PH-797804

First Posted Date
2010-10-22
Last Posted Date
2011-03-10
Lead Sponsor
Pfizer
Target Recruit Count
18
Registration Number
NCT01226693
Locations
🇸🇬

Pfizer Investigational Site, Singapore, Singapore

A Study Of Tasocitinib In Dry Eye Subjects

Phase 2
Withdrawn
Conditions
Keratoconjunctivitis Sicca
Interventions
First Posted Date
2010-10-22
Last Posted Date
2018-11-29
Lead Sponsor
Pfizer
Registration Number
NCT01226680
© Copyright 2025. All Rights Reserved by MedPath